EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|February 1, 2002
Do you perform a complete skin exam?
Over 10 years ago that question was the basis for one of my editorialsin Dermatology Times. In the ensuing years the incidence of skin cancerhas continued explosive expansion! Not only is melanoma now expanding tooccur in greater than 1:75 babies born in 2000, but it is also the mostrapidly increasing cancer in the United States.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5